Metabolic Health & GLP-1 Programme

Helix Privé's Metabolic Health and GLP-1 Programme represents a paradigm shift in how weight and metabolic dysfunction are approached in concierge medicine. Rather than treating obesity or insulin resistance as lifestyle failures, the programme recognises these as complex neuroendocrine and metabolic conditions that respond powerfully to modern pharmacological and lifestyle interventions.

The programme begins with a comprehensive metabolic assessment — fasting glucose, HbA1c, fasting insulin, HOMA-IR (insulin resistance index), full lipid panel with ApoB, liver function (including fatty liver screening via GGT and ALT), uric acid, and body composition analysis. This baseline determines the degree of metabolic dysfunction and guides the design of a personalised intervention.

GLP-1 receptor agonists — including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) — are prescribed where clinically appropriate. These medications work by mimicking the glucagon-like peptide-1 hormone, suppressing appetite, slowing gastric emptying, improving insulin sensitivity, and driving meaningful reductions in body weight and visceral fat. At Helix Privé, GLP-1 therapy is never prescribed in isolation — it is embedded within a holistic…